Table 2.
| S. no. | Compound name | Clinical phase | Sponser | Conditions |
|---|---|---|---|---|
| (1) | Rivaroxaban (BAY59-7939) | phase-III | Bayer's Johnson & Johnson Pharmaceutical Research Development | Deep vein thrombosis (DVT) or Pulmonary embolism (PE) |
| (2) | Radezolid | phase-II Complete | Rib-X pharmaceutics | Uncomplicated skin infection |
| (3) | Torezolid | phase-II | Trius Therapeutics | Complicated skin and skin-structure infections (cSSSI) |
| (4) | DA-7218 | phase-III | Dong-A Pharmaceutical | Acute bacterial skin and skin-structure infections (ABSSSI) |
| (5) | MRX-1 | phase-I | MicuRx Pharmaceutical | Bacterial infection |
| (6) | Radezolid | phase-II | Rib-X pharmaceutics | Community-acquired pneumonia |
| (7) | PNU-100480 | phase- IIa | Pfizer pharmaceutical | Pulmonary Tuberculosis |
| (8) | RX-1741 | phase- II | Rib-X pharmaceutics | Infectious skin disease |